Company Focus
argenx
Latest argenx News
Biotechnology
UK pharma major AstraZeneca is preparing to advance gefurulimab as a potential new treatment for generalized myasthenia gravis, following positive results in a global Phase III trial that could pave the way for regulatory filings. 24 July 2025
Related News
Insights
Company Spotlight
A California-based biotech company aiming to deliver a new class of RNA therapeutics.
Latest News & Features of interest to argenx
Pharmaceutical
Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1 drug Wegovy (semaglutide), as the US Food and Drug Administration (FDA) has approved an additional indication for the drug. 16 August 2025
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Pharmaceutical
Schrödinger has halted the clinical development of its oral drug SGR-2921 following the occurrence of two patient deaths in a Phase I dose-escalation trial. 15 August 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for AstraZeneca’s Fasenra (benralizumab) for use as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). 14 August 2025
Biotechnology
Pilatus Biosciences, a US biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Swiss pharma giant Roche. 14 August 2025
Biotechnology
China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren's syndrome (pSS) in China, as per the pre-specified study protocol. 14 August 2025
Pharmaceutical
Danish CNS specialist Lundbeck has reported revenue grew 14% at constant exchange rates (CER), plus 14% DKK, to 12,258 million kroner ($1,915 million) in the first six months of 2025. Growth in the USA and Europe was the driver of this strong performance. 14 August 2025
Pharmaceutical
Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately negotiated block trade, raising at least $174 million. The move is part of a plan to extend its cash runway while meeting a $100 million milestone owed to Arrowhead. 14 August 2025
Biotechnology
Sino-American biotech BeOne Medicines has announced financial results from the second quarter of 2025. 13 August 2025
Pharmaceutical
Evotec reported second-quarter 2025 revenues of $188 million, down 6% year-on-year, as strength in its biologics division partly offset weaker demand in discovery and preclinical services. Net loss narrowed to $48 million from $103 million, with earnings per share at minus $0.24. 13 August 2025
Latest In Brief for argenx
Biotechnology
US biotech Genascence today announced the US Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA). 16 July 2025
Latest Relevant Ones To Watch News
Shares of DURECT Corporation shot up 240% to $1.88 by close of trading Tuesday, after Canada’s Bausch Health agreed to acquire the Cupertino, California-based liver drug developer for an upfront cash payment of $1.75 per share. 30 July 2025
29 July 2025
16 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze